Clinical Trial Update: Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating tofacitinib for early diffuse cutaneous systemic sclerosis (dcSSc) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scleroderma
• Systemic Sclerosis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: University of Michigan | Conditions: Systemic Sclerosis, Scleroderma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-08